Clinical Trials Sponsored by Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products

Total 7 results

Chumakov Federal Scientific Center for Research...

Completed

Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19

Coronavirus Infections | Polio | Vaccine

Russian Federation
Chumakov Federal Scientific Center for Research...

Recruiting

An Open Comprative Study of the Prophylactic Efficacy and a Non-comparative Study of the Immunogenicity and Safety of the Inactivated Whole-virion Concentrated Purified Coronavirus Vaccine (CoviVac)

Coronavirus Infections | Vaccine

Russian Federation
Chumakov Federal Scientific Center for Research...

Completed

This is a Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19

Coronavirus Infections | Vaccine

Russian Federation
Chumakov Federal Scientific Center for Research...

Active, not recruiting

An Open Comparative Study of the Effectiveness and Incomparable Study of the Immunogenicity and Safety of the Vaccine (CoviVac) for Adults Aged 60 Years and Older

COVID-19 | Corona Virus Infection | Vaccine

Russian Federation
Chumakov Federal Scientific Center for Research...

Active, not recruiting

Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"

Vaccine

Russian Federation
Federal Research and Clinical Center of Physical-Chemical...
Federal Research Clinical Center of Federal Medical & Biological Agency,... and other collaborators

Unknown

Medical-biological Research of the Pathogenesis of COVID-19 Disease Caused by SARS-CoV-2 (COV2020)

Covid19

Russian Federation
National Research Center for Hematology, Russia
Federal Research Clinical Center of Federal Medical & Biological Agency,... and other collaborators

Recruiting

The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission

AML

Russian Federation

3

Subscribe